SEARCH

SEARCH BY CITATION

References

  • 1
    Schiff ER, Sorrell MF, Maddrey WC. Schiff's Diseases of the Liver. Philadelphia: Lippincott Williams & Wilkins; 2003.
  • 2
    Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000;20:17-35.
  • 3
    World Health Organization on the Internet. 2012. WHO media center. Accessed Nov. 28 2012: http://www.who.int/mediacentre/factsheets/fs164/en/.
  • 4
    Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144:705-714.
  • 5
    IOM (Institute of Medicine). 2010. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press.
  • 6
    Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Dig Liver Dis 2011;43:66-72.
  • 7
    CDC. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR 2012;61(RR-4):1-32.
  • 8
    Jacobson I, McHutchison J, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
  • 9
    Poordad F, McCone J Jr, Bacon B, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
  • 10
    Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med 2012;366:216-224.
  • 11
    Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H, et al. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012;55:742-748.
  • 12
    Suzuki F, Ikeda K, Toyota J, Karino Y, Ohmura T, Chayama K, et al. Dual oral therapy with NS5A inhibitor daclatasvir (BMS-790052) and NS3 protease inhibitor asunaprevir (BMS-650032) in HCV genotype 1b-infected null responders or patients ineligible/intolerant to peginterferon/ribavirin. J Hepatol 2012;56(Suppl 2):S7;A14.
  • 13
    Gane EJ, Stedman CAM, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
  • 14
    Poordad F, Lawitz E, Kowdley K, Everson GT, Freilich B, Cohen D, et al. 12-week interferon-free regimen of ABT-450/R + ABT-333+ribavirin achieved SVR12 in more than 90% of treatment-naive HCV genotype-1-infected subjects and 47% of previous non-responders. J Hepatol 2012;56(Suppl 2):S549;A1399.
  • 15
    Stedman CA. Prospectives for interferon-free treatment of hepatitis C. J Gastroenterol Hepatol 2013;28:38-45.
  • 16
    CDC. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. MMWR 2003;52(No. RR-3).
  • 17
    Shivkumar S, Peeling R, Jafari Y, Joseph L, Pant Pai N. Accuracy of rapid and point-of-care screening tests for hepatitis C, a systematic review and meta-analysis. Ann Intern Med 2012;157:558-566.
  • 18
    Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011;204:825-831.
  • 19
    Jewett A, Smith BD, Garfein RS, Cuevas-Mota J, Teshale EH, Weinbaum CM. Field-based performance of three pre-market rapid anti-hepatitis C antibody assays in STAHR (Study to assess hepatitis C) among young adults who inject drugs in San Diego, CA. J Clin Virol 2012;54:213-217.